Increased immune suppressive factors such as TGF-β, IL-10 and PD-L1 after C1 treatment implied that implementation of immunotherapy against these factors should occur as early as possible to improve the anti-tumor effects of chemotherapy in certain types of tumors. This evidence concerns the gene TGFB1 and neoplasm.